Pancreatic Cancer Research

ResearcherSeoul National UniversityNo recent work listed

Yung‐Jue Bang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-6000-4597; OpenAlex author ID A5050684671. Sources: OpenAlex.

Their work

Papers
17 (first author 0, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
31
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: none · 2014: 1 paper · 2015: 2 papers · 2016: 4 papers · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 4 papers · 2021: 1 paper

Papers 17

  1. Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancre… Co-author DOI 10.4143/crt.2020.928↗
  2. The prognostic role of soluble TGF-beta and its dynamics in unresectable pancreatic cancer treated with chemotherapy. Co-author DOI 10.1002/cam4.2677↗
  3. Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study. Co-author DOI 10.1111/cas.14264↗
  4. Predictive Role of Temporal Changes in Intratumoral Metabolic Heterogeneity During Palliative Chemotherapy in Patients with Advanced Pancreatic Cancer: A Prosp… Last author DOI 10.2967/jnumed.119.226407↗
  5. Therapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic Cancer. Co-author DOI 10.4143/crt.2019.183↗
  6. Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer. Co-author DOI 10.1038/s41598-019-47330-1↗
  7. Change in carbohydrate antigen 19-9 level as a prognostic marker of overall survival in locally advanced pancreatic cancer treated with concurrent chemoradioth… Co-author DOI 10.1007/s10147-017-1129-7↗
  8. More Accurate Prediction of Metastatic Pancreatic Cancer Patients' Survival with Prognostic Model Using Both Host Immunity and Tumor Metabolic Activity. Last author DOI 10.1371/journal.pone.0145692↗
  9. Outcome Analysis of Chemoradiation in Unresectable Pancreatic Cancer Focusing on Treatment Sequencing Strategy. Co-author DOI 10.21873/anticanres.11125↗
  10. The Impact of Diabetes Mellitus and Metformin Treatment on Survival of Patients with Advanced Pancreatic Cancer Undergoing Chemotherapy. Last author DOI 10.4143/crt.2014.292↗
  11. Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study. Last author DOI 10.4143/crt.2015.226↗
  12. Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index. Last author DOI 10.1371/journal.pone.0139749↗
  13. Prognostic value of splenic artery invasion in patients undergoing adjuvant chemoradiotherapy after distal pancreatectomy for pancreatic adenocarcinoma. Co-author DOI 10.4143/crt.2014.025↗
  14. The impact of body mass index dynamics on survival of patients with advanced pancreatic cancer receiving chemotherapy. Last author DOI 10.1016/j.jpainsymman.2013.08.017↗
  15. Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for… Co-author DOI 10.1007/s00280-012-1918-7↗
  16. A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysi… Last author DOI 10.1007/s10637-011-9651-3↗
  17. Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analy… Last author DOI 10.1007/s00280-011-1584-1↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Do‐Youn Oh · 16 shared papers, 2011–2021 · strength 1.24
  2. Seock‐Ah Im · 10 shared papers, 2011–2021 · strength 0.55
  3. Eui Kyu Chie · 6 shared papers, 2012–2021 · strength 0.38
  4. Kyung-Hun Lee · 6 shared papers, 2011–2021 · strength 0.37
  5. Sung Whan Ha · 5 shared papers, 2012–2021 · strength 0.31
  6. Hyunkyung Park · 3 shared papers, 2016–2020 · strength 0.29
  7. Younak Choi · 5 shared papers, 2014–2016 · strength 0.27
  8. Mei Hua Jin · 2 shared papers, 2020 · strength 0.26
  9. Kyubo Kim · 4 shared papers, 2015–2017 · strength 0.24
  10. Jin‐Young Jang · 3 shared papers, 2015–2021 · strength 0.22
  11. Sun‐Whe Kim · 3 shared papers, 2015–2021 · strength 0.22
  12. Kim Js · 2 shared papers, 2012–2021 · strength 0.15
  13. Shin Hye Yoo · 1 shared paper, 2020 · strength 0.15
  14. Hyeon Kang Koh · 2 shared papers, 2016–2017 · strength 0.14
  15. Hye Jin Choi · 1 shared paper, 2020 · strength 0.10
  16. Jen‐Shi Chen · 1 shared paper, 2020 · strength 0.10
  17. Kun‐Ming Rau · 1 shared paper, 2020 · strength 0.10
  18. Bruce Belanger · 1 shared paper, 2020 · strength 0.10
  19. Li‐Tzong Chen · 1 shared paper, 2020 · strength 0.10
  20. Chung‐Pin Li · 1 shared paper, 2020 · strength 0.10
  21. Joon Oh Park · 1 shared paper, 2020 · strength 0.10
  22. Jun Suk Kim · 1 shared paper, 2020 · strength 0.10
  23. Yan‐Shen Shan · 1 shared paper, 2020 · strength 0.10
  24. Yi‐Jun Kim · 1 shared paper, 2017 · strength 0.08
  25. Ijin Joo · 1 shared paper, 2015 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.